lanreotide [4632]



lanreotide


SMILES CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O
InChIKey PUDHBTGHUJUUFI-UHFFFAOYSA-N
Sequence ACYWKVCT
HELM PEPTIDE1{[*C(=O)C(Cc1ccc2ccccc2c1)N |$_R2;;;;;;;;;;;;;;;$|].(C,[dC]).(Y,[dY]).(W,[dW]).(K,[dK]).(V,[dV]).(C,[dC]).[*NC(C(C)O)C(=O)N |$_R1;;;;;;;;$|]}$PEPTIDE1,PEPTIDE1,2:R3-7:R3$$$V2.0

Chemical Properties

Hydrogen bond acceptors 14
Hydrogen bond donors 13
Rotatable bonds 17
Log P 0.822
Molecular weight (Da) 1095.5
Stereochemistry info unspecified


Bioactivities

Receptor Activity Source
Protein Gene Species Family Class Type Min Avg Max Database
Receptor Activity Source
Protein Gene Species Family Class Type Min Avg Max Database

lanreotide


Drug properties

Molecular type Peptide
Physiological/Surrogate Surrogate
Approved drug Yes

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0


Compound is not listed as a drug.